{"id":"adjuvanted-arepanrix","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Injection site reactions (pain, redness, swelling)"},{"rate":"20-40","effect":"Myalgia"},{"rate":"15-30","effect":"Headache"},{"rate":"15-25","effect":"Fatigue"},{"rate":"5-15","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL4650407","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated H1N1 influenza virus antigen combined with AS03, an oil-in-water adjuvant containing squalene, alpha-tocopherol, and polysorbate 80. The adjuvant enhances and accelerates the body's immune response to the viral antigen, promoting both humoral (antibody) and cellular immunity against H1N1 influenza. This formulation allows for dose-sparing while maintaining immunogenicity.","oneSentence":"Arepanrix is an adjuvanted pandemic influenza vaccine that stimulates immune response against H1N1 influenza virus through a combination of viral antigen and an immune-enhancing adjuvant.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:05.621Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pandemic H1N1 influenza prevention (2009 H1N1 pandemic strain)"}]},"trialDetails":[{"nctId":"NCT01035749","phase":"PHASE2","title":"Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-01","conditions":"Influenza","enrollment":310},{"nctId":"NCT01394614","phase":"","title":"Risk of Narcolepsy Associated With Administration of H1N1 Vaccine","status":"COMPLETED","sponsor":"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal","startDate":"2011-06","conditions":"Narcolepsy","enrollment":24},{"nctId":"NCT01000831","phase":"PHASE4","title":"Rapid Evaluation of Pandemic H1N1 Influenza Vaccines in Young Children","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2009-11","conditions":"Influenza","enrollment":167},{"nctId":"NCT01247415","phase":"","title":"Clinical Investigation on Allergic-like Reactions and Oculo-respiratory Syndrome After the H1N1 Pandemic Vaccine","status":"UNKNOWN","sponsor":"PHAC/CIHR Influenza Research Network","startDate":"2011-01","conditions":"Anaphylaxis, Allergy, Oculorespiratory Syndrome","enrollment":138},{"nctId":"NCT01016548","phase":"PHASE3","title":"Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2009-11","conditions":"Lymphoma, Multiple Myeloma, Influenza A Virus, H1N1 Subtype","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Influenza vaccine"],"phase":"marketed","status":"active","brandName":"adjuvanted Arepanrix","genericName":"adjuvanted Arepanrix","companyName":"University of British Columbia","companyId":"university-of-british-columbia","modality":"Biologic","firstApprovalDate":"","aiSummary":"Arepanrix is an adjuvanted pandemic influenza vaccine that stimulates immune response against H1N1 influenza virus through a combination of viral antigen and an immune-enhancing adjuvant. Used for Pandemic H1N1 influenza prevention (2009 H1N1 pandemic strain).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}